396 related articles for article (PubMed ID: 25531161)
21. Vaccine against peanut allergy based on engineered virus-like particles displaying single major peanut allergens.
Storni F; Zeltins A; Balke I; Heath MD; Kramer MF; Skinner MA; Zha L; Roesti E; Engeroff P; Muri L; von Werdt D; Gruber T; Cragg M; Mlynarczyk M; Kündig TM; Vogel M; Bachmann MF
J Allergy Clin Immunol; 2020 Apr; 145(4):1240-1253.e3. PubMed ID: 31866435
[TBL] [Abstract][Full Text] [Related]
22. New routes of allergen immunotherapy.
Juesas CR; Aguilar CM; Vieths S
Allergol Immunopathol (Madr); 2017 Dec; 45 Suppl 1():39-40. PubMed ID: 29129404
[No Abstract] [Full Text] [Related]
23. The peanut allergy epidemic: allergen molecular characterisation and prospects for specific therapy.
de Leon MP; Rolland JM; O'Hehir RE
Expert Rev Mol Med; 2007 Jan; 9(1):1-18. PubMed ID: 17210088
[TBL] [Abstract][Full Text] [Related]
24. Advances in the management of peanut allergy (oral immunotherapy and epicutaneous immunotherapy).
Wang J
Allergy Asthma Proc; 2020 Jan; 41(1):5-9. PubMed ID: 31888777
[No Abstract] [Full Text] [Related]
25. The 2S albumin allergens of Arachis hypogaea, Ara h 2 and Ara h 6, are the major elicitors of anaphylaxis and can effectively desensitize peanut-allergic mice.
Kulis M; Chen X; Lew J; Wang Q; Patel OP; Zhuang Y; Murray KS; Duncan MW; Porterfield HS; W Burks A; Dreskin SC
Clin Exp Allergy; 2012 Feb; 42(2):326-36. PubMed ID: 22288514
[TBL] [Abstract][Full Text] [Related]
26. Peanut allergen powder (Palforzia).
Med Lett Drugs Ther; 2020 Mar; 62(1593):33-34. PubMed ID: 32555119
[No Abstract] [Full Text] [Related]
27. Towards immunotherapy for peanut allergy.
Pons L; Palmer K; Burks W
Curr Opin Allergy Clin Immunol; 2005 Dec; 5(6):558-62. PubMed ID: 16264338
[TBL] [Abstract][Full Text] [Related]
28. Peanut gastrointestinal delivery oral immunotherapy in adolescents: Results of the build-up phase of a randomized, double-blind, placebo-controlled trial (PITA study).
Fauquert JL; Michaud E; Pereira B; Bernard L; Gourdon-Dubois N; Rouzaire PO; Rochette E; Merlin E; Evrard B;
Clin Exp Allergy; 2018 Jul; 48(7):862-874. PubMed ID: 29665158
[TBL] [Abstract][Full Text] [Related]
29. Peanut Allergy: New Developments and Clinical Implications.
Commins SP; Kim EH; Orgel K; Kulis M
Curr Allergy Asthma Rep; 2016 May; 16(5):35. PubMed ID: 27039393
[TBL] [Abstract][Full Text] [Related]
30. Peanut Allergen Threshold Study (PATS): Novel single-dose oral food challenge study to validate eliciting doses in children with peanut allergy.
Hourihane JO; Allen KJ; Shreffler WG; Dunngalvin G; Nordlee JA; Zurzolo GA; Dunngalvin A; Gurrin LC; Baumert JL; Taylor SL
J Allergy Clin Immunol; 2017 May; 139(5):1583-1590. PubMed ID: 28238744
[TBL] [Abstract][Full Text] [Related]
31. IgE binding to linear epitopes of Ara h 2 in peanut allergic preschool children undergoing oral Immunotherapy.
Dreskin SC; Germinaro M; Reinhold D; Chen X; Vickery BP; Kulis M; Burks AW; Negi SS; Braun W; Chambliss JM; Eglite S; McNulty CMG
Pediatr Allergy Immunol; 2019 Dec; 30(8):817-823. PubMed ID: 31437325
[TBL] [Abstract][Full Text] [Related]
32. Current state and advances in desensitization for peanut allergy in pediatric age.
Foti Randazzese S; Panasiti I; Caminiti L; Catamerò F; Landi M; De Filippo M; Votto M; Olcese R; Favuzza F; Giovannini M; Barberi S
Pediatr Allergy Immunol; 2024 Apr; 35(4):e14127. PubMed ID: 38646959
[TBL] [Abstract][Full Text] [Related]
33. Long-term sublingual immunotherapy for peanut allergy in children: Clinical and immunologic evidence of desensitization.
Kim EH; Yang L; Ye P; Guo R; Li Q; Kulis MD; Burks AW
J Allergy Clin Immunol; 2019 Nov; 144(5):1320-1326.e1. PubMed ID: 31493887
[TBL] [Abstract][Full Text] [Related]
34. Update on peanut allergy: Prevention and immunotherapy.
Cook QS; Kim EH
Allergy Asthma Proc; 2019 Jan; 40(1):14-20. PubMed ID: 30582491
[No Abstract] [Full Text] [Related]
35. Peanut Allergen Powder (Palforzia) for Peanut Allergy.
Erlich D
Am Fam Physician; 2022 Jan; 105(1):20-21. PubMed ID: 35029941
[No Abstract] [Full Text] [Related]
36. Allergen-specific T cells and clinical features of food allergy: Lessons from CoFAR immunotherapy cohorts.
Berin MC; Agashe C; Burks AW; Chiang D; Davidson WF; Dawson P; Grishin A; Henning AK; Jones SM; Kim EH; Leung DYM; Masilamani M; Scurlock AM; Sicherer SH; Wood RA; Sampson HA
J Allergy Clin Immunol; 2022 Apr; 149(4):1373-1382.e12. PubMed ID: 34653515
[TBL] [Abstract][Full Text] [Related]
37. The regulatory T cells induction by epicutaneous immunotherapy is sustained and mediates long-term protection from eosinophilic disorders in peanut-sensitized mice.
Dioszeghy V; Mondoulet L; Dhelft V; Ligouis M; Puteaux E; Dupont C; Benhamou PH
Clin Exp Allergy; 2014 Jun; 44(6):867-81. PubMed ID: 24666588
[TBL] [Abstract][Full Text] [Related]
38. The clinical and immunological effects of Pru p 3 sublingual immunotherapy on peach and peanut allergy in patients with systemic reactions.
Gomez F; Bogas G; Gonzalez M; Campo P; Salas M; Diaz-Perales A; Rodriguez MJ; Prieto A; Barber D; Blanca M; Torres MJ; Mayorga C
Clin Exp Allergy; 2017 Mar; 47(3):339-350. PubMed ID: 28160513
[TBL] [Abstract][Full Text] [Related]
39. Real-world safety experience with Peanut (Arachis hypogaea) Allergen Powder-dnfp in 2500 children with peanut allergy.
Jara M; Walker E; Tilles S; Anagnostou A
Ann Allergy Asthma Immunol; 2024 Jun; 132(6):778-780. PubMed ID: 38479712
[No Abstract] [Full Text] [Related]
40. Estimated risk reduction to packaged food reactions by epicutaneous immunotherapy (EPIT) for peanut allergy.
Remington BC; Krone T; Kim EH; Bird JA; Green TD; Lack G; Fleischer DM; Koppelman SJ
Ann Allergy Asthma Immunol; 2019 Nov; 123(5):488-493.e2. PubMed ID: 31442495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
